9538 Federal Register / Vol. 72, No. 41 / Friday, March 2, 2007 / Notices 

Reports Clearance Office on (410) 786–

1326. 

Written comments and 

recommendations for the proposed 

information collections must be mailed 

or faxed within 30 days of this notice 

directly to the OMB desk officer: OMB 

Human Resources and Housing Branch, 

Attention: Carolyn Lovett, New 

Executive Office Building, Room 10235, 

Washington, DC 20503, Fax Number: 

(202) 395–6974. 

Dated: February 22, 2007. 

Michelle Shortt, 

Director, Regulations Development Group, 

Office of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. E7–3654 Filed 3–1–07; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

Notice of Single-Source Grant Award 

to Louisiana, Alabama, and Mississippi 

for a Project Entitled, ‘‘Deficit 

Reduction Act Hurricane Katrina 

Healthcare Related Provider 

Stabilization’’

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: New Grant Awards. 

Funding Amount: $160,000,000. 

Period of Performance: February 12, 

2007–September 30, 2009. 

SUMMARY: The Secretary has authorized 

a total of $160 million in grant funds 

available to all three States. Based on 

each eligible IPPS hospital’s and SNF’s 

share of total Medicare inpatient 

payments in the FEMA designated 

counties in calendar year 2005 (the 

latest and most complete year of 

Medicare billing data available to us), 

this funding is being allocated for each 

State in the following proportions: 45 

percent to Louisiana ($71,633,492), 38 

percent to Mississippi ($60,556,425) and 

17 percent to Alabama ($27,810,083). 

This grant program is to fund State 

payments to general, acute care 

hospitals, and skilled nursing facilities 

in impacted communities that may face 

financial pressures because of changing 

wage rates that are not yet reflected in 

Medicare PPS payment methodologies. 

The grant funds must be used by the 

States to make payments to all Medicare 

participating general hospitals, acute 

care hospitals, and SNFs that are 

currently paid under a Medicare PPS in 

the impacted communities. States have 

some flexibility in determining the 

methodology to determine the timing 

and amount of provider payments, but 

the methodology must reflect each 

provider’s share of total Medicare 

payments during a specified period of 

time. Grant funds may not be 

distributed to hospitals and SNFs that 

are not in operation. States’ payment 

methodologies should specify the 

relevant time periods and any other 

factors that will be considered in 

distributing available grant funds 

according to the principles specified 

above, and are subject to approval by 

CMS. 

Justification for Exception to 

Competition 

The Secretary has invoked his 

authority to restore health care in 

impacted communities affected by 

Hurricane Katrina by offering this 

unique funding opportunity which will 

enable States to make payments to assist 

hospitals and SNFs that are paid under 

a Medicare PPS, with the financial 

pressures that may result from changing 

wage rates in those impacted 

communities. For the reasons cited 

above, the Secretary has directed the 

Centers for Medicare & Medicaid 

Services to offer a single-source award 

to the States of Louisiana, Alabama and 

Mississippi. 

FOR FURTHER INFORMATION CONTACT: 

Wendy J. Taparanskas, PhD., Health 

Insurance Specialist, Office of the 

Center Director, Centers for Medicaid 

and State Operations, Centers for 

Medicare & Medicaid Services, Mail 

Stop S2–26–12, 7500 Security 

Boulevard, Baltimore, MD 21244, (410) 

786–5245. 

Authority: Section 6201(a)(4) of the Deficit 

Reduction Act of 2005 (DRA) . 

(Catalog of Federal Domestic Assistance 

Program No. 93.779) 

Dated: February 13, 2007. 

Leslie V. Norwalk, 

Acting Administrator, Centers for Medicare 

& Medicaid Services. 

[FR Doc. E7–3655 Filed 3–1–07; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Determination and Findings; 

Authority To Incorporate a No-Setoff 

Commitment 

Upon the basis of the following 

findings pursuant to authority of Title 

31 U.S.C. Section 3727 and in 

accordance with the Presidential 

delegation of authority dated October 3, 

1995, as referenced in the Federal 

Acquisition Regulation 32.803(d) it is 

hereby determined that the use of a nosetoff provision is appropriate to 

facilitate the private financing of a 

steam production facility at NCIFrederick. 

Findings 

1. Despite an essentially static space 

inventory, the cost of steam under NCIFrederick’s interagency agreement with 

the Fort Detrick U.S. Army Garrison has 

increased by 70% from 2003 to 2006. In 

addition, despite numerous energy 

saving projects accomplished over the 

past 9 years, quantities of steam billed 

by the Army to the NCI have remained 

20%–30% above amounts estimated/ 

measured through engineering methods. 

2. In response to the escalation in 

steam related energy costs/quantities, a 

thorough review of steam production 

alternatives was conducted. Based on 

this analysis it was concluded that 

significant energy and cost savings 

could be achieved through the 

construction of a new steam production 

facility and the subsequent severing of 

ties to the existing Fort Detrick boiler 

plant. 

3. On behalf of Potomac Edison 

Company, APS Constellation, L.L.C. has 

proposed a privately financed Energy 

Savings Performance Contract (ESPC) to 

construct the new steam facility. 

Securing the private financing for this 

project is dependent upon incorporation 

of a no-setoff provision in the contract. 

4. Inclusion of the no-setoff provision 

will enable the Contractor to secure 

financing with an interest rate that is 

lower than the interest rate that would 

be obtained in the absence of the nosetoff provision. The Government will 

benefit directly from a lower interest 

rate in the form of lower interest 

payments over the 20-year term of the 

repayment. 

5. Incorporating a no-setoff provision 

will not increase the risk of the 

Government since the Basic Ordering 

Agreement requires that the Contractor 

guarantee that the energy and energyrelated cost savings exceed the 

payments to the Contractor during the 

performance period following 

construction of the project. In the event 

that the savings fall below the level 

guaranteed by the Contractor, the 

Contractor will be responsible for 

crediting the difference to the 

Government. 

6. In accordance with the guidance set 

forth in FAR 32.803(d), a review of the 

proposed contractor’s financial status 

revealed no significant indebtedness to 

the United States. 


pwalker on PROD1PC71 with NOTICES
Federal Register / Vol. 72, No. 41 / Friday, March 2, 2007 / Notices 9539 

Determination 

Based on the foregoing, I hereby 

determine that it is the Government’s 

best interests to approve the use of 

Alternate 1 to the Clause at FAR 52.232–

23 which authorizes incorporation of a 

no-setoff provision. 

Dated: February 22, 2007. 

Daniel J. Frasier, 

Head of the Contracting Activity, Director, 

OAMP, OA, OM, National Institutes of Health. 

[FR Doc. 07–960 Filed 3–1–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Model for Study of Glomerular 

Disorders: Conditionally-Immortalized 

Mouse Podocyte Cell Line With Tet-onRegulated Gene Expression 

Description of Technology: Podocytes, 

cells of the visceral epithelium in the 

kidneys, are a key component of the 

glomerular filtration barrier. As such, 

they play a vital role in glomerular 

disorders, which are a major cause of 

chronic kidney disease. Examples of 

these disorders include focal segmental 

glomerulosclerosis, membranous 

glomerulonephritis, minimal change 

disease, and diabetic nephropathy. 

The inventors have developed a 

conditionally-immortalized mouse 

podocyte cell line with tightly 

controlled conditional gene expression. 

The cell line has been conditionally 

immortalized through the introduction 

of the H-2Kb-tsA58 transgene, which is 

a temperature-sensitive mutant of the 

SV40T antigen. Inducible gene 

expression is tightly controlled through 

two introduced transgenes, podocinrtTA and CMV-tTS, that produce a ‘‘Teton’’ system wherein gene expression is 

induced by tetracycline or doxycycline. 

The combination of the two transgenes 

for Tet-on gene expression has resulted 

in much tighter regulation and lower 

background expression compared to 

cells carrying the podocin-rtTA 

transgene alone. 

Applications: Model system for study 

of glomerular disorders; Model system 

for podocyte cell biology. 

Market: Glomerular disorders are a 

major cause of chronic kidney disease. 

Approximately 20 to 35 percent of 

patients requiring renal replacement 

therapy have a glomerular disorder. 

Inventors: Jeffrey B. Kopp (NIDDK) et 

al. 

Relevant Publication: T Shigehara, C 

Zaragoza, C Kitiyakara, H Takahashi, H 

Lu, M Moeller, LB Holzman, and JB 

Kopp. Inducible podocyte-specific gene 

expression in transgenic mice. J Am Soc 

Nephrol. 2003 Aug;14(8):1998–2003. 

Patent Status: HHS Reference No. E–

049–2007/0—Research Tool. 

Licensing Status: This technology is 

available as a research tool under a 

Biological Materials License. 

Licensing Contact: Tara L. Kirby, 

PhD.; 301/435–4426; 

tarak@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIDDK Kidney Disease Section is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate, or commercialize a 

model system for the study of 

glomerular disorders. Please contact 

Jeffrey B. Kopp, MD, by phone (301/ 

594–3403), fax (301/402–0014) or e-mail 

(jbkopp@nih.gov) for more information. 

Latrophilin 3, a Gene Involved in 

Attention Deficit Hyperactivity 

Disorder 

Description of Technology: Attention 

Deficit Hyperactivity Disorder (ADHD) 

is the most common behavioral disorder 

in childhood, and is estimated to affect 

three to five percent of people in the 

United States, both children and adults. 

Treatment typically involves a 

combination of behavior modification, 

educational interventions, and 

medication. There are a variety of 

medications available for treatment of 

ADHD; the most frequently prescribed 

drugs are stimulants or antidepressants. 

However, currently there is no way to 

tell in advance which medication will 

be most helpful for a particular 

individual. 

The inventors have identified 

haplotypes of latrophilin 3 (LPHN3) that 

increase susceptibility for development 

of ADHD. LPHN3 is a G-protein coupled 

receptor that is specifically expressed in 

the brain’s mesolimbic system, which is 

associated with ADHD. The invention 

describes methods of identifying LPHN3 

haplotypes in an individual for 

determining susceptibility for 

development of ADHD. Identification of 

LPHN3 haplotypes in an ADHD-affected 

individual may also make possible 

individualized drug treatment plans. 

Applications: Identify individuals 

with enhanced susceptibility for ADHD; 

Use LPHN3 haplotype information to 

design individualized treatments. 

Inventors: Maximillian Muenke 

(NHGRI), Mauricio Arcos-Burgos 

(NHGRI), and F. Xavier Castellanos 

(NIMH). 

Patent Status: U.S. Provisional 

Application No. 60/850,972 filed 11 Oct 

2006 (HHS Reference No. E–312–2006/ 

0-US–01). 

Licensing Status: Available for 

exclusive or nonexclusive licensing. 

Licensing Contact: Tara Kirby, PhD.; 

301/435–4426; tarak@mail.nih.gov. 

A Fertility Test To Detect Ovarian 

Autoimmune Disease Using Human 

Recombinant MATER Protein 

Description of Technology: The 

inventors have identified MATER, a 

gene that plays an important role in 

fertility, and have shown that antibodies 

against MATER protein are detected at 

higher frequencies in women 

experiencing infertility and irregular 

menstrual periods than in healthy 

women. The discovery of MATER as an 

important factor in autoimmunemediated ovarian dysfunction will 

facilitate diagnosis and treatment of 

these disorders. In addition to its critical 

role in ovarian autoimmunity, the 

inventors have also discovered that the 

MATER gene plays an essential role in 

embryonic development. 

The invention discloses the MATER 

gene, MATER protein and MATERspecific antibodies. Also disclosed are 

methods and kits for evaluating female 

infertility through detection of an 

abnormal autoimmune response, an 

abnormal MATER gene, or abnormal 

MATER protein expression. 

Applications: Diagnostic test for 

women suffering from infertility or 

irregular menstrual periods; Tool for the 

study of early embryonic development; 


pwalker on PROD1PC71 with NOTICES